Showing 1251-1260 of 1407 results for "".
- Richard Rosen, MD, Receives Founders Award From ASRShttps://modernod.com/news/richard-rosen-md-receives-founders-award-from-asrs/2482366/The American Society of Retina Specialists (ASRS) is honoring Richard B. Rosen, MD, ScD (hon), FACS, FASRS, FARVO, CRA, the Belinda Bingham Pierce and Gerald G. Pierce Distinguished Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai, with
- AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Wet AMDhttps://modernod.com/news/asclepix-therapeutics-completes-enrollment-in-discover-trial-for-wet-amd/2482271/AsclepiX Therapeutics announced the completion of enrollment into the DISCOVER trial (NCT05859776) evaluating the safety and tolerability of three dose strengths of AXT107 (gersizangitide) for wet AMD. In the trial, 15 patients will receive either 125 µg (n=3), 250 &micr
- Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapieshttps://modernod.com/news/ray-therapeutics-closes-oversubscribed-100m-series-a-financing-to-advance-optogenetic-gene-therapies/2481621/Ray Therapeutics announced an upsized and oversubscribed $100 million Series A financing round to advance multiple programs targeting blinding diseases through clinical development. Ray Therapeutics has developed an optogenetic platform to bioengineer a pipeline of g
- Grifols Enters Into Global Collaboration and Licensing Agreement with Selagine to Develop Immunoglobulin Eye Drops to Treat Dry Eye Diseasehttps://modernod.com/news/grifols-enters-into-global-collaboration-and-licensing-agreement-with-selagine-to-develop-immunoglobulin-eye-drops-to-treat-dry-eye-disease/2481446/Spanish pharma company Grifols announced a global collaboration and licensing agreement with Selagine to treat dry eye disease (DED) with immunoglobulin eye drops. Financial terms of the deal were not disclosed. The potential immunoglobulin treatment would be G
- Staar Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEOhttps://modernod.com/news/staar-surgical-ceo-caren-mason-to-retire-tom-frinzi-appointed-new-ceo/2481302/Staar Surgical announced that President and Chief Executive Officer Caren Mason will be retiring December 31, 2022, after serving in that postion for 7 years. Staar's Board of Directors has appointed ophthalmic industry executive Thomas G. Frinzi, current Board Chair of Staar,
- Santen Filing Accepted by EMA for Review of Application for STN1013001 Cationic Emulsion of Latanoprost 50μg/mL in Glaucomahttps://modernod.com/news/santen-filing-accepted-by-ema-for-review-of-application-for-stn1013001-cationic-emulsion-of-latanoprost-50mgml-in-glaucoma/2481157/Santen Pharmaceutical announced European Medicines Agency (EMA) acceptance for review of a marketing authorization application for the use of STN1013001 for lowering of IOP in open-angle glaucoma and ocular hypertension. STN1013001 is preservative-free latanoprost 50μg/mL p
- Allergan Submits New Drug Application for Investigational Eye Drop for the Treatment of Presbyopiahttps://modernod.com/news/allergan-submits-new-drug-application-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478915/Allergan announced that it has submitted a new drug application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021. The NDA is based primarily on data from two phase 3 G
- J&J Files Single-Dose COVID-19 Vaccine for US Emergency Usehttps://modernod.com/news/jj-files-single-dose-covid-19-vaccine-for-us-emergency-use/2478836/Johnson & Johnson submitted a request to the FDA seeking an emergency-use authorization (EUA) for its COVID-19 vaccine candidate Ad26.COV2.S. Paul Stoffels, the company’s chief scientific officer, called the filing “a pivotal step toward reducing the burden of disease for people g
- DORC Announces Health Canada Approval of Tissueblue for Staining of the ILM During Vitreoretinal Surgeryhttps://modernod.com/news/dorc-announces-health-canada-approval-of-tissueblue-for-staining-of-the-ilm-during-vitreoretinal-surgery/2478799/DORC has announced that it has received notification from Health Canada that the application for Tissueblue (Brilliant Blue G Ophthalmic Solution 0.025%) has been approved and will be available later in 2021 via Innovamed, DORC’s local distributor partner. Tissueblue is the first dye approved by
- US States Sue 26 Generic Drugmakers for Alleged Price Fixinghttps://modernod.com/news/us-states-sue-26-generic-drugmakers-for-alleged-price-fixing/2479522/A coalition of 51 US states and territories filed a lawsuit in federal court in Connecticut on Wednesday, accusing 26 drug companies, including Taro, Perrigo, Novartis’ Sandoz unit, Actavis, Mylan, Teva, G&W and Glenmark, of conspiring to fix prices and allocate markets for at least 80